These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
238 related items for PubMed ID: 2495353
1. Vasorelaxant effects of cromakalim in rats are mediated by glibenclamide-sensitive potassium channels. Cavero I, Mondot S, Mestre M. J Pharmacol Exp Ther; 1989 Mar; 248(3):1261-8. PubMed ID: 2495353 [Abstract] [Full Text] [Related]
2. Hemodynamic and pharmacological evaluation of the vasodilator and vasoconstrictor effects of endothelin-1 in rats. Le Monnier de Gouville AC, Mondot S, Lippton H, Hyman A, Cavero I. J Pharmacol Exp Ther; 1990 Jan; 252(1):300-11. PubMed ID: 2405151 [Abstract] [Full Text] [Related]
3. Effects of the K+ channel activators, RP 52891, cromakalim and diazoxide, on the plasma insulin level, plasma renin activity and blood pressure in rats. Pratz J, Mondot S, Montier F, Cavero I. J Pharmacol Exp Ther; 1991 Jul 01; 258(1):216-22. PubMed ID: 1906538 [Abstract] [Full Text] [Related]
4. K+ channel opening mediates the vasorelaxant effects of nicorandil in the intact vascular system. Cavero I, Pratz J, Mondot S. Z Kardiol; 1991 Jul 01; 80 Suppl 7():35-41. PubMed ID: 1838848 [Abstract] [Full Text] [Related]
5. Antihypertensive and haemodynamic properties of the potassium channel activating (-) enantiomer of cromakalim in animal models. Clapham JC, Hamilton TC, Longman SD, Buckingham RE, Campbell CA, Ilsley GL, Gout B. Arzneimittelforschung; 1991 Apr 01; 41(4):385-91. PubMed ID: 1907150 [Abstract] [Full Text] [Related]
6. Differential effects of endothelin-1 on the vasorelaxant properties of benzopyran and non-benzopyran potassium channel openers. Lawson K, Barras M, Zazzi-Sudriez E, Martin DJ, Armstrong JM, Hicks PE. Br J Pharmacol; 1992 Sep 01; 107(1):58-65. PubMed ID: 1422579 [Abstract] [Full Text] [Related]
7. In vitro and in vivo comparison of two K+ channel openers, diazoxide and cromakalim, and their inhibition by glibenclamide. Quast U, Cook NS. J Pharmacol Exp Ther; 1989 Jul 01; 250(1):261-71. PubMed ID: 2501478 [Abstract] [Full Text] [Related]
8. Possible involvement of ATP-sensitive K+ channels in the relaxant response of dog middle cerebral artery to cromakalim. Masuzawa K, Asano M, Matsuda T, Imaizumi Y, Watanabe M. J Pharmacol Exp Ther; 1990 Nov 01; 255(2):818-25. PubMed ID: 2123008 [Abstract] [Full Text] [Related]
9. RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent. Katz LB, Giardino EC, Salata JJ, Moore JB, Falotico R. J Pharmacol Exp Ther; 1993 Nov 01; 267(2):648-56. PubMed ID: 8246137 [Abstract] [Full Text] [Related]
10. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide. Grover GJ, McCullough JR, Henry DE, Conder ML, Sleph PG. J Pharmacol Exp Ther; 1989 Oct 01; 251(1):98-104. PubMed ID: 2507775 [Abstract] [Full Text] [Related]
11. Glyburide-sensitive K+ channels in cultured rat hippocampal neurons: activation by cromakalim and energy-depleting conditions. Politi DM, Rogawski MA. Mol Pharmacol; 1991 Aug 01; 40(2):308-15. PubMed ID: 1715018 [Abstract] [Full Text] [Related]
12. The antitussive effect of cromakalim in rats is not associated with adenosine triphosphate sensitive K+ channels. Kamei J, Iwamoto Y, Narita M, Suzuki T, Misawa M, Kasuya Y. Res Commun Chem Pathol Pharmacol; 1993 May 01; 80(2):201-10. PubMed ID: 8391711 [Abstract] [Full Text] [Related]
13. Y-27152, a long-acting K+ channel opener with less tachycardia: antihypertensive effects in hypertensive rats and dogs in conscious state. Nakajima T, Shinohara T, Yaoka O, Fukunari A, Shinagawa K, Aoki K, Katoh A, Yamanaka T, Setoguchi M, Tahara T. J Pharmacol Exp Ther; 1992 May 01; 261(2):730-6. PubMed ID: 1578381 [Abstract] [Full Text] [Related]
14. Effects of several potassium channel openers and glibenclamide on the uterus of the rat. Piper I, Minshall E, Downing SJ, Hollingsworth M, Sadraei H. Br J Pharmacol; 1990 Dec 01; 101(4):901-7. PubMed ID: 2128195 [Abstract] [Full Text] [Related]
15. Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts? Tosaki A, Szerdahelyi P, Engelman RM, Das DK. J Pharmacol Exp Ther; 1993 Dec 01; 267(3):1355-62. PubMed ID: 8263798 [Abstract] [Full Text] [Related]
16. Pharmacologic profiles of YM934, a novel potassium channel opener. Uchida W, Masuda N, Taguchi T, Shibasaki K, Shirai Y, Asano M, Matsumoto Y, Tsuzuki R, Fujikura T, Takenaka T. J Cardiovasc Pharmacol; 1994 Feb 01; 23(2):180-7. PubMed ID: 7511745 [Abstract] [Full Text] [Related]
17. Effect of potassium channel blockade on the anti-ischemic actions of mechanistically diverse agents. Sargent CA, Smith MA, Dzwonczyk S, Sleph PG, Grover GJ. J Pharmacol Exp Ther; 1991 Oct 01; 259(1):97-103. PubMed ID: 1920138 [Abstract] [Full Text] [Related]
18. Effects of BRL 34915 (cromakalim) on renal hemodynamics and function in anesthetized dogs. Hayashi K, Matsumura Y, Yoshida Y, Ohyama T, Hisaki K, Suzuki Y, Morimoto S. J Pharmacol Exp Ther; 1990 Mar 01; 252(3):1240-6. PubMed ID: 2108239 [Abstract] [Full Text] [Related]
19. 8-(Diethylamino)-octyl-3,4,5-trimethoxybenzoate inhibits cromakalim-induced 86Rb efflux from the rat aorta. Lodge NJ, Halaka NN. J Pharmacol Exp Ther; 1993 Jun 01; 265(3):1399-405. PubMed ID: 8510016 [Abstract] [Full Text] [Related]
20. Potassium channel blockade and halothane vasodilation in conducting and resistance coronary arteries. Larach DR, Schuler HG. J Pharmacol Exp Ther; 1993 Oct 01; 267(1):72-81. PubMed ID: 8229789 [Abstract] [Full Text] [Related] Page: [Next] [New Search]